GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
GeneTether Therapeutics Inc. reported its Q2 2024 financials, revealing total assets of $1.1 million and a decision to cease the development of its GeneTether platform to focus on strategic transactions aimed at enhancing shareholder value. The company is expanding its search beyond life sciences to increase the likelihood of a successful transaction.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.
